Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

GLP-1 Drugs

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill

Investors focus on Lilly’s reliance on two injections for more than half of 2025 sales.

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

WHO Endorses Long-Term GLP-1 Use for Obesity as Indian Ruling Opens Production and Safety Alerts Expand

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

GLP-1 Drugs Linked to Lower Overall Cancer Risk in JAMA Oncology Analysis